&lt;p&gt;Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer&lt;/p&gt;

Wang, Yuanyuan; Fu, Min; Liu, Jingjing; Yang, Yining; Yu, Yancun; Li, Jinyu; Pan, Wei-San; Fan, Lei; Li, Guiru; Li, Xuetao; Wang, Xiaobo

doi:10.2147/ijn.s194304

Cited by 49 publications

(24 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results showed that dioscin‐loaded liposomes caused a notable decrease in the number of invasive cells (Figure C). Among all liposomal formulations, RPV‐modified epirubicin and dioscin co‐delivery liposomes showed the strongest invasive and migratory inhibitory effect on A549 cells, with a relative migration rate of 14.91 ± 5.02% (Figure D), confirming our previous findings that dioscin plays a key role in inhibiting A549 cell invasion and migration …”

Section: Resultssupporting

confidence: 88%

“…The targeted molecule of 2‐distearoyl‐ sn ‐glycero‐3‐phosphoethanolamine‐ N ‐methoxy‐poly(ethylene glycol 2000)‐RPV (DSPE‐PEG 2000 ‐RPV) was synthesized by binding DSPE‐PEG 2000 ‐COOH and the RPV peptide, following a previously reported protocol . Briefly, DSPE‐PEG 2000 ‐COOH and RPV peptide (1:1 molar ratio) were dissolved in anhydrous dimethylformamide.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

et al. 2020

Self Cite

View full text Add to dashboard Cite

| 621 wileyonlinelibrary.com/journal/cas | INTRODUC TI ONLung cancer is one of the most common malignancies and a leading cause of cancer-related death worldwide. 1 Among all lung cancers, approximately 85% are non-small cell lung cancer (NSCLC), for which morbidity is significantly higher than for small cell lung cancer. 2 In the past decade, targeted therapy, immunotherapy, and similar approaches rapidly developed to become the new treatment modalities for NSCLC. Despite recent developments and improvements in diagnosis and treatment, prospects for patients with NSCLC are dismal and the 5-year overall survival rate is only 15%-18%. 3,4 Rapid growth and metastasis are basic biological characteristics of malignant tumors, including NSCLC. 5 It is well known that angiogenesis plays a key role in cancer growth and metastasis. Anti-angiogenesis treatment has evolved to achieve encouraging results, but despite the widespread application of anti-angiogenic drugs, they have not attained satisfactory efficacy. [6][7][8] This means that alternative nutrient supply channels support tumor growth.Vasculogenic mimicry (VM) is defined as formation of vascu- lar-like structures lined with tumor cells without the presenceThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractChemotherapy for non-small cell lung cancer (NSCLC) is far from satisfactory, mainly due to poor targeting of antitumor drugs and self-adaptations of the tumors.Angiogenesis, vasculogenic mimicry (VM) channels, migration, and invasion are the main ways for tumors to obtain nutrition. Herein, RPV-modified epirubicin and dioscin co-delivery liposomes were successfully prepared. These liposomes showed ideal physicochemical properties, enhanced tumor targeting and accumulation in tumor sites, and inhibited VM channel formation, tumor angiogenesis, migration and invasion. The liposomes also downregulated VM-related and angiogenesis-related proteins in vitro. Furthermore, when tested in vivo, the targeted co-delivery liposomes increased selective accumulation of drugs in tumor sites and showed extended stability in blood circulation. In conclusion, RPV-modified epirubicin and dioscin co-delivery liposomes showed strong antitumor efficacy in vivo and could thus be considered a promising strategy for NSCLC treatment. K E Y W O R D Sangiogenesis, cell-penetrating peptide, co-delivery liposome, non-small cell lung cancer, vasculogenic mimicry

show abstract

Section: Resultssupporting

confidence: 88%

Section: Methodsmentioning

confidence: 99%

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Guo et al revealed that the decrease of VM and the expression of VE-cadherin, EphA2, MMP-2, and MMP-9 in both Rg3-treated tumor xenografts and vitro cells [116]. Moreover, dioscin is an extract from traditional medicinal plants and showed as an inhibitor in the process of VM formation in daunorubicin and dioscin codelivery liposomes [117]. Melittin has been confirmed as an inhibitor in the process of tumor angiogenesis and metastasis.…”

Section: Clinical Significance Of Vm In Cancermentioning

confidence: 99%

Vasculogenic mimicry in carcinogenesis and clinical applications

et al. 2020

View full text Add to dashboard Cite

Distinct from classical tumor angiogenesis, vasculogenic mimicry (VM) provides a blood supply for tumor cells independent of endothelial cells. VM has two distinct types, namely tubular type and patterned matrix type. VM is associated with high tumor grade, tumor progression, invasion, metastasis, and poor prognosis in patients with malignant tumors. Herein, we discuss the recent studies on the role of VM in tumor progression and the diverse mechanisms and signaling pathways that regulate VM in tumors. Furthermore, we also summarize the latest findings of non-coding RNAs, such as lncRNAs and miRNAs in VM formation. In addition, we review application of molecular imaging technologies in detection of VM in malignant tumors. Increasing evidence suggests that VM is significantly associated with poor overall survival in patients with malignant tumors and could be a potential therapeutic target.

show abstract

“…Finally, the cellular uptake and distribution were analyzed by a fluorescence confocal microscope (Nikon Cl-si TE2000, Tokyo, Japan). 19,23 Destructing Effects in A549 Cells Spheroids…”

Section: Cellular Uptake and Distributionmentioning

confidence: 99%

“…The half inhibitory concentration of cells (IC 50 ) was calculated, and each assay was repeated in triplicate. 23,25…”

Section: Cytotoxicity Assaymentioning

confidence: 99%

<p>Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC</p>

Kong

Zhang

Chu

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Non-small cell lung cancer (NSCLC) is one of the most lethal types of cancer with highly infiltrating. Chemotherapy is far from satisfactory, vasculogenic mimicry (VM) and angiogenesis results in invasion, migration and relapse. Purpose: The objective of this study was to construct a novel CPP (mmp) modified vinorelbine and dioscin liposomes by two new functional materials, DSPE-PEG 2000-MAL and CPP-PVGLIG-PEG 5000 , to destroy VM channels, angiogenesis, EMT and inhibit invasion and migration. Methods and Results: The targeting liposomes could be enriched in tumor sites through passive targeting, and the positively charged CPP was exposed and enhanced active targeting via electrostatic adsorption after being hydrolyzed by MMP2 enzymes overexpressed in the tumor microenvironment. We found that CPP (mmp) modified vinorelbine and dioscin liposomes with the ideal physicochemical properties and exhibited enhanced cellular uptake. In vitro and in vivo results showed that CPP (mmp) modified vinorelbine and dioscin liposomes could inhibit migration and invasion of A549 cells, destroy VM channels formation and angiogenesis, and block the EMT process. Pharmacodynamic studies showed that the targeting liposomes had obvious accumulations in tumor sites and magnificent antitumor efficiency. Conclusion: CPP (mmp) modified vinorelbine plus dioscin liposomes could provide a new strategy for NSCLC.

show abstract

<p>Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer</p>

Cited by 49 publications

References 49 publications

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

Vasculogenic mimicry in carcinogenesis and clinical applications

<p>Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC</p>

Contact Info

Product

Resources

About